education_image.jpg

Webinar 3 - IGF-1 Deficiency – Knowns and Unknowns, a cased-based symposium

 

Webinar 3 - IGF-1 Deficiency – Knowns and Unknowns, a cased-based symposium

 

 

The ESPE Education and Training Committee are delighted to announce the third in their ESPE Connect webinar series.  These regular webinars offer high-quality scientific and educational content from our world-leading paediatric endocrinologists. ESPE Connect will present the latest developments covering all areas of paediatric endocrinology that you can view whilst it’s broadcast live or on-demand at your convenience.

Date: 27 January 2022

Time: 16:00-17:30 CET /15:00-16:30 GMT UK time

IGF-1 Deficiency - Knowns and unknowns, a case-based symposium

Programme: 

  • Welcome - Dr Senthil Senniappan (Liverpool, UK) - ESPE Connect Webinar Convenor
  • Introduction to today's webinar - Professor Michel Polak (Paris, France)
  • Genetics – Professor Helen Storr (London, UK)
  • Diagnosis - Professor Peter Bang (Linköping, Sweden)
  • Treatment - Professor Joachim Woelfle (Erlangen, Germany)
  • Panel Discussion
  • Webinar Close - Professor Michel Polak (Paris, France)

Each talk will be 20 minutes with Q&A for each speaker taking place during the panel discussion.

Our Speakers

Professor Helen Storr

Helen Storr is a Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University London (QMUL) and St. Bartholomew’s and the Royal London Hospitals. She completed a PhD in molecular endocrinology at the William Harvey Research Institute, Barts and the London School of Medicine funded by a Wellcome Trust Research Training Fellowship.

In 2006, she was awarded a HEFCE Clinical Senior Lectureship and was appointed Senior Clinical Lecturer at QMUL and Honorary Consultant in Paediatric Endocrinology at Barts and the Royal London Hospitals. Professor Storr was promoted to Academic Reader in 2014 and Professor in 2020. She was awarded the 2011 European Society for Paediatric Endocrinology (ESPE) Young Investigator Award and a 5-year NIHR Advanced Fellowship in 2019. Her clinical paediatric endocrine practice is broad with key clinical interests in disorders of growth and puberty, paediatric Cushing’s syndrome and adrenal disorders.

She leads an active programme of clinical and laboratory research and directs an international genetic diagnostic service for patients with undiagnosed short stature. Her current research focuses on the recognition and diagnosis of growth disorders in children. She is medical advisor for the Child Growth Foundation (CGF).

Learning objectives of Professor Storr’s Talk

  • To review the genetic defects which present with severe growth hormone insensitivity (GHI)
  • To review the genetic defects which cause 'non-classical' or mild GHI
  • To discuss the expanding range of overlapping GHI disorders which can be identified by genetic investigation

Professor Peter Bang

Peter Bang is Professor of Pediatrics and Academic Head of Division of Pediatrics as well as Head of Div of Childrens and Womens Health,
Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Sweden. He is senior consultant and is heading the Pediatric Endocrinology team. He has more than 30 years research experience in the GH-IGF-field and has a publication list of more than 60 peer-reviewed papers. He graduated from the Engineering School, Technical University of Copenhagen and the University of Copenhagen Medical School, Denmark and did his PhD with Professor Kerstin Hall at the Karolinska Institute, Stockholm, Sweden. After Postdoctoral training with Professor Ron Rosenfeld, Stanford University, CA, USA, he did his Pediatric Endocrine training at the Karolinska University Hospital. Peter has a long-lasting interest in the regulation of IGF-I bioactivity with focus on growth disorders and diabetes.

Professor Joachim Woelfle

Joachim Woelfle is Professor of Paediatrics at the Friedrich-Alexander-University of Erlangen in Germany.

Prof. Woelfle received his medical degree in 1994 from the Albert-Ludwigs-University of Freiburg (Germany). Following his pediatric residency he completed clinical fellowships in pediatric endocrinology/diabetology, neuropaediatrics and pediatric intensive care. From 2000 to 2003, he worked as a research fellow on growth hormone-induced signal transduction in Peter Rotwein’s group at Oregon Health & Science University (Portland, USA) sponsored by an ESPE research fellowship. From 2004 to 2019, he was head of the Paediatric Endocrinology and Diabetology Division of the Children’s University Hospital in Bonn. 2019 he became director of the Children’s and Adolescent hospital and Chair of Paediatrics at the Friedrich-Alexander-University of Erlangen in Germany.

Professor Woelfle’s scientific interests cover the topics of perinatal endocrinology, paediatric obesity, endocrine disorders in critically ill children and in particular physiology and pathophysiology of growth. For his work on GH-regulated transcription he and members of his group received several awards, including the Juergen Bierich award of the Working Group on Paediatric Endocrinology (APE).

Professor Woelfle has published numerous original articles, reviews and textbook chapters in the field of paediatric endocrinology with a focus on growth-related disorders. He is treasurer and past-President of the Board of the German Society of Paediatric Endocrinology (DGKED) and serves as counselor or board-member in several other scientific endocrinology or nutrition-related boards.

Learning Objectives of Professor Woelfle’s Talk

  • To learn about efficacy and limitations of IGF-1 treatment in SPIGFD
  • To inform on monitoring and safety profile during mecasermin therapy.

Our ESPE Connect webinars are free to attend for our ESPE members and colleagues from affiliated societies. If you’re not a member you can join, and receive all of the additional member benefits, or you can register for the webinar for a small fee of €25.00.

This ESPE Connect Webinar is kindly supported by